Skip to main content
SpringerLink
Log in

Hypoglycemia in Type 1 Diabetes Mellitus

Pathophysiology and Prevention

  • Review Article
  • Published:
Treatments in Endocrinology

Abstract

Spontaneous hypoglycemia is uncommon in the general (nondiabetic) population, but iatrogenic hypoglycemia is rife in patients with type 1 diabetes mellitus, among whom hypoglycemia constitutes a barrier to optimal glycemic control. The obligate dependence on exogenous insulin, together with the current imperfection in insulin therapies, generates degrees of blood glucose fluctuations that often exceed physiological boundaries in these patients. Downward swings in blood glucose levels, if sustained, result in hypoglycemia and significant morbidity and mortality. Hypoglycemia in type 1 diabetes indicates an imbalance between caloric supply and glucose use in response to insulin or exercise. Counterregulatory mechanisms that auto-correct iatrogenic hypoglycemia often become progressively impaired in these patients. This defective counterregulation, together with the imperfections in insulin delivery, set the stage for significant morbidity from iatrogenic hypoglycemia. Recurrent episodes of iatrogenic hypoglycemia induce a state of hypoglycemia unawareness and defective counterregulation, which defines the syndrome of hypoglycemia-associated autonomic failure (HAAF). The reduced awareness of, and counterregulatory responses to, hypoglycemia in patients with HAAF lead to worsening episodes of severe hypoglycemia.

Approaches to the prevention of hypoglycemia include glucose monitoring, patient education, meal planning, and medication adjustment. In patients with HAAF, scrupulous avoidance of iatrogenic hypoglycemia may restore the symptomatic and counterregulatory responses to hypoglycemia. Behavioral training focusing on recognition of the more subtle symptoms and signs of evolving hypoglycemia may be beneficial to some patients with HAAF. A methodical search for the pattern and etiology of iatrogenic hypoglycemia is a prerequisite for the identification of the best preventive approach. With proper education, patients with type 1 diabetes and their physicians can learn to prevent or minimize the risk of hypoglycemia while pursuing excellence in glycemic control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

Notes

  1. The use of brand names is for product identification purposes only and does not imply endorsement.

References

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86

    Article  Google Scholar 

  2. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17

    Article  PubMed  CAS  Google Scholar 

  3. The United Kingdom Prospective Diabetes Study Research Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53

    Article  Google Scholar 

  4. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968–83

    Article  Google Scholar 

  5. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12

    Article  PubMed  CAS  Google Scholar 

  6. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 1–6

    Article  Google Scholar 

  7. Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378–89

    Article  PubMed  CAS  Google Scholar 

  8. Cryer PE. Hypoglycemia: pathophysiology, diagnosis and treatment. New York: Oxford University Press, 1997

    Google Scholar 

  9. MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238–45

    Article  PubMed  CAS  Google Scholar 

  10. Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101–8

    Article  PubMed  CAS  Google Scholar 

  11. Abaira C, Colwell JA, Nuttall FQ, et al. Veterans affairs cooperative study on glycémic control and complications in type II diabetes: results of the feasibility trial. Diabetes Care 1995; 18: 1113–23

    Article  Google Scholar 

  12. Hepburn DA, MacLeod KM, Pell ACH, et al. Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993; 10: 231–7

    Article  PubMed  CAS  Google Scholar 

  13. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902–12

    Article  PubMed  CAS  Google Scholar 

  14. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–86

    Article  Google Scholar 

  15. Kaufman FR, Austin J, Neinstein A, et al. Nocturnal hypoglycemia detected with the continuous glucose monitoring system in pediatrie patients with type 1 diabetes. J Pediatr 2002; 141: 625–30

    Article  PubMed  CAS  Google Scholar 

  16. Due to fear of fatal hypoglycemia, parents tolerate dangerous blood glucose values [in German]. MMW Fortschr Med 2002; Apr 4; 144 (14): 53

    Google Scholar 

  17. Ramsey S, Summers KH, Leong SA, et al. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002; 25: 23–9

    Article  PubMed  Google Scholar 

  18. The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450–9

    Google Scholar 

  19. Miihlhauser I, Overmann H, Bender R, et al. Risk factors for severe hypoglycaemia in adult patients with type 1 diabetes: a prospective population based study. Diabetologia 1997; 41: 1274–82

    Google Scholar 

  20. Allen C, LeCaire T, Palta M, et al. Risk factors for frequent and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 1878–81

    Article  PubMed  CAS  Google Scholar 

  21. Bischof MG, Bernroider E, Ludwig C, et al. Effect of near physiologic insulin therapy on hypoglycemia counterregulation in type-1 diabetes. Horm Res 2001; 56: 151–8

    Article  PubMed  CAS  Google Scholar 

  22. Leese GP, Wang J, Broomhall J, et al. Incidence of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabet Med 2002; 19: 12–3

    Article  Google Scholar 

  23. Hardy KJ, Burge MR, Boyle PJ, et al. A treatable cause of recurrent severe hypoglycemia. Diabetes Care 1994 Jul; 17: 722–4

    Article  PubMed  CAS  Google Scholar 

  24. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia 2003; 46: 89–96

    PubMed  CAS  Google Scholar 

  25. Nordfeldt S, Samuelsson U. Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 274–8

    Article  PubMed  CAS  Google Scholar 

  26. Cryer PE. Hypoglycemia begets hypoglycemia in IDDM. Diabetes 1993; 42: 1691–3

    PubMed  CAS  Google Scholar 

  27. Cryer PE. Hypoglycemia unawareness in IDDM. Diabetes Care 1993; 3: 40–7

    Google Scholar 

  28. Cryer PE. Banting lecture: hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378–89

    Article  PubMed  CAS  Google Scholar 

  29. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomie failure in insulin dependent diabetes mellitus. J Clin Invest 1993; 91: 819–28

    Article  PubMed  CAS  Google Scholar 

  30. Rattarasarn C, Dagogo-Jack S, Zachwieja JJ, et al. Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomie activation. Diabetes 1994; 43: 809–18

    Article  PubMed  CAS  Google Scholar 

  31. Cryer PE. Hypoglycemia-associated autonomie failure in insulin-dependent diabetes mellitus. Adv Pharmacol 1998; 42: 620–2

    Article  PubMed  CAS  Google Scholar 

  32. Cryer PE, Childs BP. Negotiating the barriers of hypoglycemia in diabetes. Diabetes Spectrum 2002; 15: 20–7

    Article  Google Scholar 

  33. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697–703

    Article  PubMed  CAS  Google Scholar 

  34. White NH, Skor D, Cryer PE, et al. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308: 485–91

    Article  PubMed  CAS  Google Scholar 

  35. Towler DA, Havlin CE, Cryer PE. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42: 1791–8

    Article  PubMed  CAS  Google Scholar 

  36. Schwartz NS, Clutter WE, Shah SD, et al. The glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest 1987; 79: 777–81

    Article  PubMed  CAS  Google Scholar 

  37. Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res 1997; 29: 92–6

    Article  PubMed  CAS  Google Scholar 

  38. Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135–41

    Article  PubMed  CAS  Google Scholar 

  39. Gerich JE, Mokan M, Veneman T, et al. Hypoglycemia unawareness. Endocrine Rev 1991; 12: 356–71

    Article  CAS  Google Scholar 

  40. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994; 17: 734–55

    PubMed  CAS  Google Scholar 

  41. Hepburn DA, Patrick AW, Eadington DW, et al. Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomie neuropathy. Diabet Med 1990; 7: 711–7

    Article  PubMed  CAS  Google Scholar 

  42. Muhlhauser I, Berger M, Sonnenberg GE, et al. Incidence and management of severe hypoglycemia in 434 patients with insulin-dependent diabetes mellitus. Diabetes Care 1985; 8: 268–73

    Article  PubMed  CAS  Google Scholar 

  43. MacLeod KM. Hypoglycaemia unawareness: causes, consequences and treatment. J R Coll Physicians Lond 2000; 34: 245–50

    PubMed  CAS  Google Scholar 

  44. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991; 40(2): 223–6

    Article  PubMed  CAS  Google Scholar 

  45. Ovalle F, Fanelli CG, Paramore DS, et al. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998; 47: 1472–9

    Article  PubMed  CAS  Google Scholar 

  46. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683–9

    Article  PubMed  CAS  Google Scholar 

  47. Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycemia unawareness in patients with long duration insulin-dependent diabetes mellitus. Lancet 1994; 344: 283–7

    Article  PubMed  CAS  Google Scholar 

  48. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426–34

    Article  PubMed  CAS  Google Scholar 

  49. Maggs DG, Jacob R, Rife F, et al. Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue. Diabetes 1997; 46: 70–6

    Article  PubMed  CAS  Google Scholar 

  50. Amiel SA, Tamborlane WV, Sacca L, et al. Hypoglycemia and glucose counterregulation in normal and insulin-dependent diabetic subjects. Diabetes Metab Rev 1988; 4: 71–89

    Article  PubMed  CAS  Google Scholar 

  51. McGregor VP, Banarer S, Cryer PE. Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab 2002; 282: E770–7

    PubMed  CAS  Google Scholar 

  52. Gerich JE, Langlois M, Naocco C, et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171–3

    Article  PubMed  CAS  Google Scholar 

  53. Fanelli CG, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia following institution of rational intensive therapy in IDDM. Diabetologia 1994; 37: 1265–76

    Article  PubMed  CAS  Google Scholar 

  54. Simonson DC, Tamborlane WV, DeFronzo RA, et al. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Ann Intern Med 1985; 103: 184–90

    PubMed  CAS  Google Scholar 

  55. Ryder RE, Owens DR, Hayes TM, et al. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. BMJ 1990; 301: 783–7

    Article  PubMed  CAS  Google Scholar 

  56. Hoeldtke RD, Boden G. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med 1994; 120: 512–7

    PubMed  CAS  Google Scholar 

  57. Herold K, Polonsky KS. Does tight glucose control enhance brain sensitivity to low glucose? Diabetes Care 1991; 14: 141–3

    PubMed  CAS  Google Scholar 

  58. Boyle PJ, Kempers SF, O’Connor AM, et al. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 1726–31

    Article  PubMed  CAS  Google Scholar 

  59. Boyle PJ, Nagy RJ, O’Connor AM, et al. Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc Natl Acad Sci U S A 1994; 91: 9352–6

    Article  PubMed  CAS  Google Scholar 

  60. Borg WP, During MJ, Sherwin RS, et al. Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. J Clin Invest 1994; 93: 1677–82

    Article  PubMed  CAS  Google Scholar 

  61. Borg MA, Sherwin RS, Borg WP, et al. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997; 99: 361–5

    Article  PubMed  CAS  Google Scholar 

  62. Amiel SA, Tamborlane WV, Simonson DC, et al. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987; 316: 1376–83

    Article  PubMed  CAS  Google Scholar 

  63. Powers WJ, Dagogo-Jack S, Markham J, et al. Cerebral transport and metabolism of 1-11C-D-glucose during stepped hypoglycemia. Ann Neurol 1995; 38: 599–609

    Article  PubMed  CAS  Google Scholar 

  64. Segel SA, Fanelli CG, Dence CS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001; 50: 1911–7

    Article  PubMed  CAS  Google Scholar 

  65. Davis SN, Shavers C, Davis B, et al. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997; 100: 429–38

    Article  PubMed  CAS  Google Scholar 

  66. Sandoval DA, Ping L, Neill AR, et al. Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes 2003; 52: 2198–204

    Article  PubMed  CAS  Google Scholar 

  67. Raju B, McGregor VP, Cryer PE. Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Diabetes 2003 Aug; 52: 2083–9

    Article  PubMed  CAS  Google Scholar 

  68. Sherwin RS, Tamborlane WV, Ahern J. Lessons from glucose monitoring at night. Diabetes Care 1987; 10: 249–51

    PubMed  CAS  Google Scholar 

  69. Pillar G, Schuscheim G, Weiss R, et al. Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. J Pediatr 2003; 142: 163–8

    Article  PubMed  Google Scholar 

  70. Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin dependent) diabetes mellitus: magnitude, frequency, variability and dependence on glucose counterregulation and insulin sensitivity. Diabetes 1991; 34: 21–8

    CAS  Google Scholar 

  71. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657–62

    Article  PubMed  CAS  Google Scholar 

  72. Harsch IA, Stocker S, Radespiel-Troger M, et al. Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med 2002; 252: 352–60

    Article  PubMed  CAS  Google Scholar 

  73. Ryan CM, Williams TM, Finegold DN, et al. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 329–34

    Article  PubMed  CAS  Google Scholar 

  74. Perros P, Deary IJ, Sellar RJ, et al. Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care 1997; 20: 1013–8

    Article  PubMed  CAS  Google Scholar 

  75. Jones TW, McCarthy G, Tamborlane WV, et al. Mild hypoglycemia and impairment of brain stem and cortical evoked potentials in healthy subjects. Diabetes 1990; 39: 1550–5

    Article  PubMed  CAS  Google Scholar 

  76. Dagogo-Jack S. Diabetes mellitus and related disorders. In: Ahya S, Flood K, Paranjothi S, editors. Washington manual of medical therapeutics. 30th ed. New York: Lippincott, 2001: 455–72

    Google Scholar 

  77. Bolli GB. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 1999; 22Suppl. 2: B43–52

    PubMed  Google Scholar 

  78. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26Suppl. 1: S51–61

    Google Scholar 

  79. Kalergis M, Schiffrin A, Gougeon R, et al. Impact of bedtime snack composition on prevention of nocturnal hypoglycemia in adults with type 1 diabetes undergoing intensive insulin management using lispro insulin before meals: a randomized, placebo-controlled, crossover trial. Diabetes Care 2003; 26: 9–15

    Article  PubMed  Google Scholar 

  80. Gray RO, Butler PC, Beers TR, et al. Comparison of the ability of bread versus bread plus meat to treat and prevent subsequent hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1508–11

    Article  PubMed  CAS  Google Scholar 

  81. Kaufman FR, Halvorsen M, Kaufman ND. A randomized, blinded trial of uncooked cornstarch to diminish nocturnal hypoglycemia at diabetes camp. Diabetes Res Clin Pract 1995; 30: 205–9

    Article  PubMed  CAS  Google Scholar 

  82. Detlofson I, Kroon M, Aman J. Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Acta Paediatr 1999 Jun; 88(6): 595–7

    Article  PubMed  CAS  Google Scholar 

  83. Ververs MTC, Rouwé C, Smit GPA. Complex carbohydrates in the prevention of nocturnal hypoglycemia in diabetic children. Eur J Clin Nutr 1993; 47: 268–73

    PubMed  CAS  Google Scholar 

  84. Matyka KA, Wigg I, Pramming S, et al. Cognitive function and mood after profound nocturnal hypoglycemia in prepubertal children with conventional insulin treatment for diabetes. Arch Dis Child 1999; 81: 138–42

    Article  PubMed  CAS  Google Scholar 

  85. Holloszy JO, Kohrt WM, Hansen PA. The regulation of carbohydrate and fat metabolism during and after exercise. Front Biosci 1998; 3: D1011–27

    PubMed  CAS  Google Scholar 

  86. Chipkin SR, Klugh SA, Chasan-Taber L. Exercise and diabetes. Cardiol Clin 2001; 19: 489–505

    Article  PubMed  CAS  Google Scholar 

  87. American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care 2003; 26Suppl. 1: S73–7

    Google Scholar 

  88. McGregor VP, Greiwe JS, Banarer S, et al. Limited impact of vigorous exercise on defenses against hypoglycemia: relevance to hypoglycemia-associated autonomic failure. Diabetes 2002; 51: 1485–92

    Article  PubMed  CAS  Google Scholar 

  89. Riddell MC, Bar-Or O, Ayub BV, et al. Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Int J Sport Nutr 1999; 9: 24–34

    PubMed  CAS  Google Scholar 

  90. Hernandez JM, Moccia T, Fluckey JD, et al. Fluid snacks to help persons with type 1 diabetes avoid late onset postexercise hypoglycemia. Med Sci Sports Exerc 2000; 32: 904–10

    PubMed  CAS  Google Scholar 

  91. Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care 1994; 17: 924–37

    PubMed  CAS  Google Scholar 

  92. Brunelle RL, Llewelyn J, Anderson Jr JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726–31

    Article  PubMed  CAS  Google Scholar 

  93. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904–9

    Article  PubMed  CAS  Google Scholar 

  94. Heller SR, Amiel SA, Mansell P. Effect of the fast acting insulin analogue lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy: UK Lispro Study Group. Diabetes Care 1999; 22: 1607–11

    Article  PubMed  CAS  Google Scholar 

  95. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639–43

    Article  PubMed  CAS  Google Scholar 

  96. Dagogo-Jack S, Askari H, Morrill B, et al. Physiological responses during hypoglycemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes Obes Metab 2000; 2: 373–83

    Article  PubMed  CAS  Google Scholar 

  97. Yki-Järvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bed time insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: the HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130–6

    Article  PubMed  Google Scholar 

  98. Vague P, Selam JL, Skeie S, et al. Detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590–6

    Article  PubMed  CAS  Google Scholar 

  99. Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analogue insulin detemir with NPH insulin. Diabetes Care 2001; 24: 296–301

    Article  PubMed  CAS  Google Scholar 

  100. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19: 746–51

    Article  PubMed  CAS  Google Scholar 

  101. Saleh TY, Cryer PE. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997; 20: 1231–6

    Article  PubMed  CAS  Google Scholar 

  102. Robertson RP. Prevention of recurrent hypoglycemia in type 1 diabetes by pancreas transplantation. Acta Diabetol 1999; 36: 3–9

    Article  PubMed  CAS  Google Scholar 

  103. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 Jul 27; 343: 230–8

    Article  PubMed  CAS  Google Scholar 

  104. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50:710–9

    Article  PubMed  CAS  Google Scholar 

  105. McCrimmon RJ, Sherwin RS. Effect of pancreatic transplantation on counterregulatory hormonal responses to hypoglycaemia. Acta Diabetol 1999; 36: 11–20

    Article  PubMed  CAS  Google Scholar 

  106. Meyer C, Hering BJ, Grossmann R, et al. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation 1998; 66: 233–40

    Article  PubMed  CAS  Google Scholar 

  107. Paty BW, Lanz K, Kendall DM, et al. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001; 72: 1103–7

    Article  PubMed  CAS  Google Scholar 

  108. Bolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes. Diabetes 1984; 33: 732–7

    Article  PubMed  CAS  Google Scholar 

  109. Fritsche A, Stumvoll M, Haring HU, et al. Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab 2000; 85: 523–5

    Article  PubMed  CAS  Google Scholar 

  110. Lingenfelser T, Buettner UW, Uhl H, et al. Recovery of hypoglycaemia-associated compromised cerebral function after a short interval of euglycaemia in insulin-dependent diabetic patients. Electroencephalogr Clin Neurophysiol 1994; 92: 196–203

    Article  PubMed  CAS  Google Scholar 

  111. Dagogo-Jack S, Fanelli CG, Cryer PE. Durable reversal of hypoglycemia unawareness in type 1 diabetes. Diabetes Care 1999; 22: 866–7

    Article  PubMed  CAS  Google Scholar 

  112. Debrah K, Sherwin RS, Murphy J, et al. Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet 1996; 347: 19–24

    Article  PubMed  CAS  Google Scholar 

  113. Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000; 23: 455–9

    Article  PubMed  CAS  Google Scholar 

  114. de Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002; 51: 790–6

    Article  PubMed  Google Scholar 

  115. Kinsley BT, Weinger K, Bajaj M, et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999; 22: 1022–8

    Article  PubMed  CAS  Google Scholar 

  116. Clarke WL, Cox DJ, Gonder-Frederick L, et al. Biopsychobehavioral model of risk of severe hypoglycemia: self-management behaviors. Diabetes Care 1999; 22: 580–4

    Article  PubMed  CAS  Google Scholar 

  117. Fritsche A, Stumvoll M, Renn W, et al. Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia. Diabetes Res Clin Pract 1998; 40: 129–35

    Article  PubMed  CAS  Google Scholar 

  118. Cox DJ, Gonder-Frederick L, Polonsky W, et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24: 637–42

    Article  PubMed  CAS  Google Scholar 

  119. Wiethop BV, Cryer PE. Alanine and terbutaline in the treatment of hypoglycemia in IDDM. Diabetes Care 1993; 16: 1131–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Dagogo-Jack is supported in part by National Institutes of Health (NIH) Clinical Research Center Grant MO1 RR00211. The author has no conflicts of interest directly relevant to the content of this review. No funding was received solely to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Medicine (Endocrinology) & General Clinical Research Center, University of Tennessee Health Science Center, Memphis, Tennessee, USA

    Samuel Dagogo-Jack

Authors
  1. Samuel Dagogo-Jack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Dagogo-Jack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dagogo-Jack, S. Hypoglycemia in Type 1 Diabetes Mellitus. Mol Diag Ther 3, 91–103 (2004). https://doi.org/10.2165/00024677-200403020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200403020-00004

Keywords

Search

Navigation